Core Viewpoint - Ovarian cancer is the deadliest gynecological malignancy, with 324,938 new cases and 206,834 deaths globally in 2022. Current treatment options for platinum-resistant ovarian cancer are limited, highlighting the urgent need for new effective anti-angiogenic drugs [2][3]. Group 1: Clinical Research Findings - A phase 3 clinical trial named SCORES demonstrated that Suvemcitug, an anti-VEGF antibody, combined with chemotherapy significantly improves overall survival (OS) and progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer [3][6]. - The trial involved 421 patients across 55 medical centers in China, with a random assignment to receive either Suvemcitug plus chemotherapy or a placebo plus chemotherapy [6][7]. - Results showed a median PFS of 5.5 months for the Suvemcitug group compared to 2.7 months for the placebo group, and median OS of 15.3 months versus 14.0 months, respectively [7]. Group 2: Safety and Tolerability - The most common grade ≥3 adverse events in the Suvemcitug plus chemotherapy group were neutropenia and leukopenia, with no grade 5 adverse events related to Suvemcitug reported [9]. - Overall, the phase 3 trial indicates that the combination of Suvemcitug with chemotherapy significantly improves PFS and OS in platinum-resistant ovarian cancer patients, with manageable toxicity [9].